Travaux scientifiques

Prof. Dr. Meral Beksaç

912 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: A randomized evaluation of early vs late administration of recombinant human G-CSF

    Bone Marrow Transplantation, 2009

    DOI 10.1038/bmt.2009.161 PMID 19597420 12 citations (Europe PMC) Source : ORCID

  2. Predisposing or Protective HLA Specificities Associated with the Development of Multiple Myeloma (MM)

    Clinical Lymphoma & Myeloma, 2009

    DOI 10.1016/s1557-9190(11)70687-4 Source : ORCID

  3. Quantification of mesenchymal stem cells in grafts adds to the benefits of haematopoietic stem cell and T-cell analysis in prediction of the duration of aplasia but not probability of acute graft-versus-host disease: preliminary results

    Bone Marrow Transplantation, 2009

    Source : ORCID

  4. Randomized comparison of bone marrow and peripheral blood stem cells for treatment of leukaemia - long-term follow-up results on survival, GvHD and late effects

    Bone Marrow Transplantation, 2009

    Source : ORCID

  5. Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation in Myeloma: A Prospective Trial

    Clinical Lymphoma & Myeloma, 2009

    DOI 10.1016/s1557-9190(11)70446-2 Source : ORCID

  6. TRACKING OF DONOR TYPE GREN FLUORESCENT AND LUCIFERASE POSITIVE MARROW MONONUCLEAR OR MESENCHYMAL STEM CELLS IN POSTMORTEM SPINAL CORD HISTOPATHOLOGICAL SECTIONS FOR DETERMINATION OF REGENERATION IN A SPINAL CORD INJURY MODEL

    Haematologica, 2009

    Source : ORCID

  7. Tandem Autologous(ASCT)/Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT

    Blood, 2009

    DOI 10.1182/blood.v114.22.52.52 21 citations (OpenAlex) Source : ORCID

  8. The effect of rituximab in first line therapy to results of autologus haematopoietic stem cell transplantation in relapsed non-Hodgkin's lymphoma patients

    Bone Marrow Transplantation, 2009

    Source : ORCID

  9. Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.

    Blood, 2009

    DOI 10.1182/blood.v114.22.4846.4846 Source : OpenAlex

  10. Stress-Induced Release of Cortisol and Prolactin during Dilatation and Curettage under General and Local Anesthesia

    Neuropsychobiology, 2008

    DOI 10.1159/000118084 PMID 6493478 2 citations (Europe PMC) Source : OpenAlex

  11. Allogeneic haematopetic cell transplantation in elderly patients: validation of survival according to Sorror comorbidity index

    Bone Marrow Transplantation, 2008

    Source : ORCID

  12. Autologous stem cell transplantation (ASCT) vs ASCT followed by reduced-intensity conditioning allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: preliminary analysis of a prospective controlled trial by the EBMT

    Bone Marrow Transplantation, 2008

    Source : ORCID

  13. COMPARATIVE ANALYSIS OF MESENCHYMAL STEM CELL CONTENT DETECTED BY FLOW CYTOMETRY IN UMBILICAL CORD BLOOD, G-CSF MOBILIZED PERIPHERAL BLOOD, ADULT AND PEDIATRIC BONE MARROW OF HEALTHY DONORS

    Haematologica, 2008

    Source : ORCID

  14. Cord blood banking

    Vox Sanguinis, 2008

    DOI 10.1111/j.1423-0410.2008.01106.x PMID 19138265 24 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  15. Do the febrile neutropenic episodes during mobilisation have any effect on autologous stem cell collection yield in patients with myeloma and lymphoma?

    Bone Marrow Transplantation, 2008

    Source : ORCID

  16. FACTORS INVOLVED IN RESPONSE TO THALIDOMIDE IN MYELODYSPLASTIC SYNDROME: IMPACT OF HLA AND PROGNOSTIC FACTORS

    Haematologica, 2008

    Source : ORCID

  17. Familial multiple myeloma associated with disorders of chronic inflammation: First report from Turkey

    Clinical Lymphoma and Myeloma, 2008

    DOI 10.3816/clm.2008.n.033 PMID 18765313 4 citations (Europe PMC) Source : ORCID

  18. HLA Specificities and Predisposition to the Development of Multiple Myeloma (MM)

    Blood, 2008

    Source : ORCID

  19. HLA-A, -B, -C, -DR haplotypes, linkeage and frequencies observed in Ankara University, Turkey: a report from Tran

    Tissue Antigens, 2008

    Source : ORCID

  20. High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

    Blood, 2008

    Source : ORCID

  21. Long Term Outcome and Late Effects in Patients Transplanted with Filgrastim-Mobilized Blood or Bone Marrow Treated in a Randomized Trial. A Study from the EBMT Late Effects Working Party

    Blood, 2008

    Source : ORCID

  22. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: An analysis of 10 549 patients from the International Myeloma Working Group

    Blood, 2008

    DOI 10.1182/blood-2007-03-081018 PMID 18268097 156 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  23. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

    Haematologica, 2008

    DOI 10.3324/haematol.11080 PMID 18268286 367 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  24. Response to induction, early mobilisation and pre-autologous transplant use of bortezomib and/or thalidomide prolong progression free and/or overall survival in myeloma

    Bone Marrow Transplantation, 2008

    Source : ORCID

  25. T-helper-1 (Th1) and Th2 cytokines after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

    Turkish Journal of Hematology, 2008

    Source : ORCID

  26. THE IMPACT OF THE DISPARITIES OF SHORT TANDEM REPEATS (STR) BETWEEN DOONOR-RECIPIENT PAIR ON THE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) OUTCOME

    Biology of Blood and Marrow Transplantation, 2008

    DOI 10.1016/j.bbmt.2007.12.311 Texte intégral en libre accèsSource : ORCID

  27. The evolving treatment paradigm of multiple myeloma: From past to present and future

    Turkish Journal of Hematology, 2008

    Source : ORCID

  28. The relation between the disparities of short tandem repeats between donor-recipient pair and the allogeneic haematopoietic cell transplantation outcome

    Bone Marrow Transplantation, 2008

    Source : ORCID

  29. Vitiligo after hematopoietic cell transplantation: Six cases and review of the literature

    Dermatology, 2008

    DOI 10.1159/000117705 PMID 18285686 29 citations (Europe PMC) Source : ORCID

  30. High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC and GIMEMA Leukemia Groups)

    Blood, 2008

    DOI 10.1182/blood.v112.11.134.134 8 citations (OpenAlex) Source : OpenAlex

  31. Factors Involved in Response to Thalidomide in Myelodysplastic Syndrome: Impace of HLA and Prognostic Factors

    Blood, 2008

    DOI 10.1182/blood.v112.11.5079.5079 Source : OpenAlex

  32. Allogeneic hematopoietic cell transplantation in imatinib era: A single center comparative analysis of imatinib receiving patients to imatinib naive patients

    Biology of Blood and Marrow Transplantation, 2007

    Source : ORCID

  33. Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma

    Blood, 2007

    DOI 10.1182/blood.v110.11.5096.5096 Source : ORCID

  34. Case matched comparison for analysing the impact of regimen intensity of allogeneic haematopoietic cell transplantation in chronic myeloid leukaemia

    Bone Marrow Transplantation, 2007

    Source : ORCID

  35. Clinical outcome following implantation of autologous bone marrow mononuclear cells into the traumatized spinal cord: 6-18 month follow-up results of four consecutive patients

    Bone Marrow Transplantation, 2007

    Source : ORCID

  36. Dna hyperploidy is associated with both high plasma cell percentage & high β2 microglobulin and impairs survival in myeloma patientstreated with or without transplantation

    Haematologica, 2007

    Source : ORCID

  37. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia [6]

    Leukemia and Lymphoma, 2007

    DOI 10.1080/10428190701370597 PMID 17613776 8 citations (Europe PMC) Source : ORCID

  38. HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO)and use of the Luminex technology.

    Methods in molecular medicine, 2007

    DOI 10.1007/978-1-59745-223-6_5 PMID 17666743 26 citations (Europe PMC) Source : ORCID

  39. HLA-DR15 and HLA-DR3 are observed more frequently among allo-transplanted compared to auto-transplanted or non-transplanted patients, a finding observed in myeloma, but not CML, cases from various countries

    Tissue Antigens, 2007

    Source : ORCID

  40. HemHLA (R) (Ankara, tr): a flexible software for HLA typing laboratories and registries that supports storage, transport and search functions on donor/recipient data

    Tissue Antigens, 2007

    Source : ORCID

  41. High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis

    Respirology, 2007

    DOI 10.1111/j.1440-1843.2007.01151.x PMID 17986116 9 citations (Europe PMC) Source : ORCID

  42. Identification of bone marrow derived nonhematopoietic cells by double labeling with immunohistochemistry and in situ hybridization.

    Methods in molecular medicine, 2007

    DOI 10.1007/978-1-59745-223-6_11 PMID 17666749 Source : ORCID

  43. Impact of HLA on availability of a donor, graft versus host disease frequency, and survival among 611 myeloma patients transplanted at three institutions from three continents

    Haematologica, 2007

    Source : ORCID

  44. Impact of histopathological subtype of cutaneous chronic GvHD on alloHSCT outcome: Iichenoid versus scleradermoid

    Bone Marrow Transplantation, 2007

    Source : ORCID

  45. P007 Both HLA DRB1*11 and DRB1*15 are observed more frequently among patients with myelodysplastic syndrome compared to healthy controls

    Leukemia Research, 2007

    DOI 10.1016/s0145-2126(07)70077-2 Source : ORCID

  46. PET/CT imaging in multiple myeloma-preliminary results

    European Journal of Nuclear Medicine and Molecular Imaging, 2007

    Source : ORCID

  47. Phosphorylated retinoblastoma expression by plasma cells is associated with a trend for advanced stages, refractoriness and shorter survival following chemotherapy in patients with newly diagnosed myeloma

    Haematologica, 2007

    Source : ORCID

  48. Report of the european myeloma network (EMN) workshop on multiparametric flow cytometry in multiple myeloma and related disorders

    Haematologica, 2007

    Source : ORCID

  49. Sequence-specific primed PCR (PCR-SSP) typing of HLA Class I and Class II alleles.

    Methods in molecular medicine, 2007

    DOI 10.1007/978-1-59745-223-6_4 PMID 17666742 4 citations (Europe PMC) Source : ORCID

  50. The conditioning regimen intensity of allogeneic hematopoietic cell transplantation (Allo-HCT) in chronic myeloid leukemia (CML): The historical case matched comparison of ablative versus reduced intensity regimen

    Biology of Blood and Marrow Transplantation, 2007

    DOI 10.1016/j.bbmt.2006.12.227 Texte intégral en libre accèsSource : ORCID